Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0054 | 0.0037 | 0.5 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0252 | 0.449 | 0.447 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.0325 | 0.6134 | 1 |
Onchocerca volvulus | Vesicular acetylcholine transporter homolog | 0.0496 | 1 | 0.5 |
Trypanosoma brucei | mitochondrial DNA polymerase beta-PAK | 0.0154 | 0.2282 | 0.3682 |
Echinococcus multilocularis | vesicular acetylcholine transporter | 0.0496 | 1 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0054 | 0.0037 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0252 | 0.449 | 0.447 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0054 | 0.0037 | 1 |
Leishmania major | mitochondrial DNA polymerase beta | 0.0325 | 0.6134 | 1 |
Echinococcus granulosus | vesicular acetylcholine transporter | 0.0496 | 1 | 1 |
Schistosoma mansoni | vesicular acetylcholine transporter | 0.0496 | 1 | 1 |
Trypanosoma brucei | mitochondrial DNA polymerase beta | 0.0325 | 0.6134 | 1 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta, putative | 0.0325 | 0.6134 | 1 |
Brugia malayi | MH2 domain containing protein | 0.0252 | 0.449 | 0.447 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | 0.0154 | 0.2282 | 0.3682 |
Trypanosoma cruzi | mitochondrial DNA polymerase beta-PAK, putative | 0.0056 | 0.0074 | 0.0061 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0171 | 0.2673 | 0.5 |
Loa Loa (eye worm) | vesicular acetylcholine transporter unc-17 | 0.0496 | 1 | 1 |
Leishmania major | mitochondrial DNA polymerase beta-PAK, putative | 0.0154 | 0.2282 | 0.3682 |
Mycobacterium ulcerans | hypothetical protein | 0.0171 | 0.2673 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0054 | 0.0037 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.